Adherence to denosumab in the treatment of osteoporosis and its utilization in the Czech Republic

References

• Kanis JA, McCloskey EV, Johansson H, et al.; on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013;24:23-57
   PubMed Web of Science ®Google Scholar
• Kanis JA, Compston J, Cooper C, et al. The burden of fractures in the European Union in 2010. Osteoporos Int 2012;23(Suppl 2):S57
   Google Scholar
• Stepan J, Vaculik J, Pavelka K, et al. Hip fracture incidence from 1981 to 2009 in the Czech Republic as a basis of the country-specific FRAX model. Calcif Tissue Int 2012;90:365-72
   PubMed Web of Science ®Google Scholar
• Fuksa L, Vytrisalova M, Hendrychova T, et al. Consumption of osteoanabolic drugs and strontium ranelate in the treatment of osteoporosis in the Czech Republic in 2005–2011. Acta Pol Pharm 2014;71:329-35
   PubMed Web of Science ®Google Scholar
• Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health 2011;14:571-81
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles’ heel of anti-fracture efficacy. Osteoporos Int 2007;18:711-19
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007;82:1493-501
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Gathon HJ, Bruyere O, et al. Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence. Value Health 2010;13:394-401
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Martin J, McClung MR, et al.; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65
   PubMed Web of Science ®Google Scholar
• Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab 2013;98:4483-92
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Toulis KA, Polyzos SA, et al. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag 2012;8:295-306
   PubMed Web of Science ®Google Scholar
• State Institute for Drug Control. Lists of drugs and medical foods reimbursed from the public health insurance. Available at: http://www.sukl.cz/sukl/seznam-leciv-a-pzlu-hrazenych-ze-zdrav-pojisteni [Last accessed April 2015]
   Google Scholar
• European Medicines Agency; PROLIA EMEA/H/C/001120. Product information, EPAR and assessment history. Available at: http://www.ema.europa.eu/ema/ [Last accessed April 2015]
   Google Scholar
• WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. Introduction to drug utilization research. Oslo: World Health Organization, 2003. ISBN 82-8082-039-6
   Google Scholar
• Czech National Bank. Exchange rates – averages, yearly history. Available at: https://www.cnb.cz/en/index.html [Last accessed April 2015]
   Google Scholar
• Kendler DL, McClung MR, Freemantle N, et al.; DAPS Investigators. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011;22:1725-35
   PubMed Web of Science ®Google Scholar
• Freemantle N, Satram-Hoang S, Tang ET, et al.; DAPS Investigators. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 2012;23:317-26
   PubMed Web of Science ®Google Scholar
• Kendler DL, Macarios D, Lillestol MJ, et al. Influence of patient perceptions and preferences for osteoporosis medication on adherence behavior in the Denosumab Adherence Preference Satisfaction study. Menopause 2014;21:25-32
   PubMed Web of Science ®Google Scholar
• Ringe JD, Farahmand P. Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile. Rheumatol Int 2014;34:727-32
   PubMed Web of Science ®Google Scholar
• Silverman S, Gold DT. Compliance and persistence with osteoporosis medications: a critical review of the literature. Rev Endocr Metab Disord 2010;11:275-80
   PubMed Web of Science ®Google Scholar
• Levis S, Theodore G. Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. J Manag Care Pharm 2012;18(4 Suppl B):S1-15; discussion S13
   Google Scholar
• Hiligsmann M, Reginster JY. Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium. Pharmacoeconomics 2011;29:895-911
   PubMed Web of Science ®Google Scholar
• Jönsson B, Ström O, Eisman JA, et al. Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 2011;22:967-82
   PubMed Web of Science ®Google Scholar
• Parthan A, Kruse M, Yurgin N, et al. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 2013;11:485-97
   PubMedGoogle Scholar
• Confavreux CB, Canoui-Poitrine F, Schott AM, et al. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. Eur J Endocrinol 2012;166:735-41
   PubMed Web of Science ®Google Scholar
• Cotté FE, Fardellone P, Mercier F, et al. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int 2010;21:145-55
   PubMed Web of Science ®Google Scholar
• Hadji P, Claus V, Ziller V, et al. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporos Int 2012;23:223-31
   PubMed Web of Science ®Google Scholar
• van Boven JF, de Boer PT, Postma MJ, Vegter S. Persistence with osteoporosis medication among newly-treated osteoporotic patients. J Bone Miner Metab 2013;31:562-70
   PubMed Web of Science ®Google Scholar
• Ziller V, Kostev K, Kyvernitakis I, et al. Persistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German database. Int J Clin Pharmacol Ther 2012;50:315-22
   PubMed Web of Science ®Google Scholar
• Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis – a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int 2011;22:1537-46
   PubMed Web of Science ®Google Scholar
• Foster SA, Foley KA, Meadows ES, et al. Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 2011;22:551-7
   PubMed Web of Science ®Google Scholar
• Tanaka I, Sato M, Sugihara T, et al. Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study. J Osteoporos 2013;2013:654218
   PubMedGoogle Scholar
• Burden AM, Paterson JM, Solomon DH, et al. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada. Osteoporos Int 2012;23:1075-82
   PubMed Web of Science ®Google Scholar
• Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010;21:1943-51
   PubMed Web of Science ®Google Scholar
• Curtis JR, Yun H, Matthews R, et al. Adherence with intravenous zoledronate and intravenous ibandronate in the United States Medicare population. Arthritis Care Res (Hoboken) 2012;64:1054-60
   PubMed Web of Science ®Google Scholar
• Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int 2014;25:1807-12
   PubMed Web of Science ®Google Scholar
• Lai PS, Chua SS, Chew YY, Chan SP. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women. J Clin Pharm Ther 2011;36:557-67
   PubMed Web of Science ®Google Scholar
• Dezii CM. Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 2011;10:42-5
   Google Scholar
• Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 2003;14:259-62
   PubMed Web of Science ®Google Scholar
• Vytrisalova M, Blazkova S, Palicka V, et al. Self-reported compliance with osteoporosis medication – qualitative aspects and correlates. Maturitas 2008;60:223-9
   PubMed Web of Science ®Google Scholar
• Life tables for the CR since 1920. Czech Statistical Office. Available at: https://www.czso.cz [Last accessed April 2015]
   Google Scholar
• General Health Insurance Company of the Czech Republic. Annual reports. Available at: http://www.vzp.cz/en/annual-reports.php; http://www.vzp.cz/o-nas/dokumenty/vyrocni-zpravy [Last accessed April 2015]
   Google Scholar